Cost-effectiveness of brief structured interventions to discontinue long-term benzodiazepine use: an economic analysis alongside a randomised controlled trial [version 1; peer review: 2 approved]

Dominic Trépel\textsuperscript{1-3}, Shehzad Ali\textsuperscript{4}, Simon Gilbody\textsuperscript{4}, Alfonso Leiva\textsuperscript{5}, Dean Mcmillan\textsuperscript{4}, Ferran Bejarano\textsuperscript{6}, Ermengol Sempere\textsuperscript{7}, Caterina Vicens\textsuperscript{5}

\textsuperscript{1}School of Medicine, Trinity College Dublin, Dublin, D02 PN40, Ireland
\textsuperscript{2}Global Brain Health Institute, Trinity College Dublin, Dublin, D02 PN40, Ireland
\textsuperscript{3}Global Brain Health Institute, University of California, San Francisco, San Francisco, CA, USA
\textsuperscript{4}Mental Health and Addictions Research Group, Department of Health Sciences, University of York, UK, Heslington, York, YO10 5DD, UK
\textsuperscript{5}Instituto de Investigación Sanitaria de Palma, Palma, 07120, Spain
\textsuperscript{6}Institut Català de la Salut, DAP Camp de Tarragona, Catalunya, Catalunya, Spain
\textsuperscript{7}Conselleria de Sanitat Universal i Salut Pública, Paterna Health Care Centre, Valencia, 46010, Spain

Abstract

Background: In Spain, long-term use of benzodiazepine is prevalent in 7% of the population; however, this longer-term use lacks clinical benefits, costs €90 million per year and side-effects further add extra cost through adverse health outcomes. This study aims to estimate the cost-effectiveness of primary care services stepped dose reduction of long-term benzodiazepines using either Structured Interview with Follow-up (SIF) or Without Follow-up (SIW), compared to Treatment as Usual (TAU).

Design: Cost-effectiveness analysis was conducted alongside randomised control utilizing data from three arm cluster randomized trial.

Setting: Primary care.

Participants: 75 general practitioners were randomised to one of the three arms (TAU, SIW, SIF).

Measurements: Cost and Cost per Quality-Adjusted Life Year (QALY)

Results: Compared to usual care, providing SIW per participant costs an additional €117.94 and adding patient follow-up, €218.4. As a result of intervention, participants showed a gain of, on average, for SIW 0.0144 QALY (95% CI -0.0137 to 0.0425) and for SIF 0.0340 QALY (0.0069 to 0.0612). The Incremental Cost Effectiveness Ratio was €8190.28/QALY (SIW) and €6423.53/QALY (SIF). At the Spanish
Corresponding author: Dominic Trépel (trepeld@tcd.ie)

Author roles: Trépel D: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Software, Validation, Visualization, Writing – Original Draft Preparation; Ali S: Methodology, Resources, Writing – Original Draft Preparation; Gilbody S: Funding Acquisition, Investigation, Project Administration, Supervision, Writing – Original Draft Preparation; Leiva A: Data Curation, Funding Acquisition, Investigation, Project Administration, Writing – Original Draft Preparation; Mcmillan D: Conceptualization, Data Curation, Funding Acquisition, Investigation, Project Administration, Writing – Original Draft Preparation; Bejarano F: Conceptualization, Data Curation, Funding Acquisition, Investigation, Project Administration, Resources, Writing – Original Draft Preparation; Sempere E: Conceptualization, Data Curation, Investigation, Resources, Writing – Original Draft Preparation; Vicens C: Conceptualization, Data Curation, Funding Acquisition, Investigation, Project Administration, Resources, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: Trial funded by the Carlos III Health Institute of the Ministry of Economy and Competitiveness (PS09/00947). Economic analysis funded by University of York. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Trépel D et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Trépel D, Ali S, Gilbody S et al. Cost-effectiveness of brief structured interventions to discontinue long-term benzodiazepine use: an economic analysis alongside a randomised controlled trial [version 1; peer review: 2 approved] HRB Open Research 2020, 3:33 https://doi.org/10.12688/hrbopenres.13049.1

First published: 03 Jun 2020, 3:33 https://doi.org/10.12688/hrbopenres.13049.1

reimbursement threshold (€45,000 per QALY) the chance interventions are cost effective is 79.8% for SIW and 97.7% for SIF.

Conclusions: Brief structured interventions to discontinue long-term benzodiazepine use represent value for money, particularly with scheduled follow-up appointments, and would represent a cost-effective investment by the Spanish healthcare to reduce prevalence of long-term use.

Keywords
Cost effectiveness analysis, Randomised Control Trial, Benzodiazepine, Brief structured interventions, Discontinue of long-term
Introduction
Long-term prescription of benzodiazepines has significant negative outcomes, causing significant costs to healthcare and wider society; however, many physicians continue to prescribe these and patients wishing to withdraw rarely receive advice or support1. The prevalence of long-term benzodiazepine use in Europe2 remains high despite policy recommendations to limit their use4,7.

In Spain, long-term use is extensive, with more than 7% of the population using them regularly8,9, whereas in the United Kingdom, Germany or Netherlands (where policies aim to restrict use), prevalence of their use is less than 2%-2.3. Based on the cost of long-term benzodiazepine prescription alone, we estimate the cost in Spain is over €70 million per annum and, if the consequences of associated morbidities were considered, the full economic cost to healthcare is much higher19.

Evidence suggests that long-term use has a lack of clinical benefits1, and guidelines clearly recommend prescribing on a short-term basis. Given the implications associated with long-term use, several programs designed to taper off the use of benzodiazepines have been developed, which have been demonstrated to be effective and safe12,13. However the uptake and use of such interventions is not widespread. A case for the use of such interventions could be supported by robust evidence of cost effectiveness to show that this was an efficient use of finite healthcare resources. To our knowledge there are no full economic evaluations in this area. Economic evidence on benzodiazepine cessation programs report predominantly how costs vary by level of complexity, as studies have tended to report the absolute costs of programs (as opposed to the incremental cost over Treatment as Usual (TAU)). Full economic evaluations are therefore required14,15.

A clinical trial in primary care has already been reported, which assesses the effectiveness of two interventions to discontinue long-term benzodiazepine use. The two programs evaluated were found to be more effective than usual care in stopping long-term benzodiazepine use in patients without severe co-morbidity16. Having established that both programs are clinically effective in reducing long-term use, the question then arises as to whether they are also cost-effective.

To our knowledge, this is the first cost-effectiveness analysis of benzodiazepine cessation programs in Spain. To inform policy, we simultaneously examine generic health gains (expressed in Quality-Adjusted Life Years (QALYs))17,18 and associated costs to healthcare; this aims to inform the decision-makers by comparing the Incremental Cost Effectiveness Ratio (ICER) against willingness-to-pay threshold19-25. The clinical trial assessed the effectiveness of two interventions in primary care using ‘discontinuation of benzodiazepine use’ as the primary outcome. The economic evaluation adopted the perspective of the Spanish Health system and Spanish unit costs were applied to the cost of general practitioner (GP) training, per-protocol cost of GP intervention, costs of follow up visit and the cost associated with benzodiazepine use.

Methods
Participants and interventions
The clinical trial has been described by Vicens et al. (2014)16. Briefly, a three-arm, parallel, multicentre, cluster-randomised trial was carried out in Spain, which aimed to compare the effectiveness of two brief structured, tapering interventions delivered by the GP, to discontinue long-term benzodiazepine use versus a control group that received TAU. The current study presents the economic analysis conducted alongside this randomised controlled trial from a health systems perspective.

The interventions included a structured educational interview with gradual dose reduction either (i) with follow-up visits (Structured Interview with Follow-up - SIF) or (ii) with written instructions (Structured Interview without Follow-up - SIW) instead of a follow-up visit. The initial interventions’ visit in both groups lasted about 20 minutes; SIF arm patients scheduled 12 minutes follow-up appointments every 2–3 weeks until the end of the dose reduction and each appointment had reinforced education, reassured patients regarding withdrawal symptoms and obtained patient agreement for the next step in dose reduction. The patients in the SIW group received written instructions reinforcing educational information at their first and only contact with their GP, along with a tailored gradual dose-reduction until benzodiazepine cessation.

GPs from 21 primary care centres in the three regions of Spain were enrolled and, in total, 75 GPs were randomised to one of the three arms (TAU, SIW, SIF). Patients eligible for the trial were aged 18 to 80 years and had been taking benzodiazepines daily for at least 6 months and did not have a severe mental or physical illness. GPs were randomised once the patients were included, and GPs from the intervention groups were scheduled to a two-hour training session in benzodiazepine withdrawal. GPs of the SIF arm received an additional 30 minutes training in how to proceed in the follow-up visits. Because each GP treated several patients, the GP time cost was spread across patients seen by the GP during this study.

Resource use and associated unit costs
Evidence in the literature would suggest that long-term benzodiazepine use may have negative health consequences that would have cost consequences to health service. However, we restrict our consideration of cost to consider whether the health gains within the trial period justify the cost of the cessation programs plus subsequent benzodiazepine use.

The costs of the cessation programs include GP training and subsequent patient follow-ups, if any, with the GP for benzodiazepine discontinuation. The cost of the training programs per GP was calculated. The training programs were run in three regions as group GP-delivered workshops and the required resources were considered to calculate the program cost (includes cost of training, trainers’ time, travel and accommodation and all other overhead costs).

Patient resource use (both in terms of training time and follow-up visits) were multiplied by the unit cost of a GP visit to
obtain total GP cost. The unit cost of GP visit can vary across Spanish regions and are published in official regional bulletin by each region. The cost associated with training GPs in SIF and SIW were based on the trainer time (in all cases trainers were GPs, so an hourly rate of €75 per hour was used), travel and accommodation costs by regions where training was provided, and cost associated with administration to organise and provide the workshops.

In Spain, benzodiazepine prescribing is regulated and only formulations with a reference price (published authorised by the Spanish Agency of Drugs and Sanitary products (AEMPS)) are available. The nomenclature web application of the AEMPS was used to obtain benzodiazepines cost for this price year. Retrospective levels of benzodiazepine use by participants in the randomised control trial was assessed at baseline, 6 month and 12 months; these consumption patterns were reviewed and confirmed by prescription claims in the clinical records.

Costs are presented in Euros (€) for the price year 2013 and for international comparison, equivalent costs are presented in Pound Sterling (GBP) and US Dollar (USD). Since the follow-up period lasted 1 year, no extrapolation over time was executed, discounting was not necessary. Analysis was conducted using Stata 13.

Outcomes: mapping generic health state utilities from condition specific measure
As the original trial does not include a measure of individuals’ generic health-state (e.g. EQ-5D), to provide outcomes that have broad policy-relevant application (e.g. QALYs), we evaluated several mapping functions to allow cross walking of a condition-specific measure to obtain a utility score. Specifically, Hospital Anxiety and Depression Scale (HADS) scores were available in the clinical trial, which were used to estimate generic health utility outcomes.

To identify an up-to-date and appropriate method to map clinical trial outcomes onto equivalent generic health states, HERC Database of Mapping Studies (Version 3.0 - June 2014) was searched. Within this resource, we identified that Brazier et al (2014) systematically reviewed studies with estimation of mapping functions in mentally ill populations. Specifically, the authors critically appraised two studies mapping HADS to generic preference-based measures of health and based on their appraisal, and after comparing post-estimation statistics from each study, we selected to utilise the regression analysis of EQ-5D and HADS. The mapping algorithm utilises the specific scores from the two subscales for depression (HADS-D) and anxiety (HADS-A) to estimate EQ5D index. The results provide individual utility at each time point, and by applying an area under the curve approach these utility values were used to estimate QALYs.

Cost effectiveness analysis
Unadjusted Incremental Cost Effectiveness Ratio (ICER) for each intervention group (SIW and SIF) are calculated against TAU using the following formula:

\[
\text{ICER} = \frac{C_I - C_T}{E_I - E_T}
\]

where C is the costs and E is the effects (as QALYs) in the Intervention (I) or TAU(T).

To estimate the joint distributions of cost and QALYs, non-parametric bootstrapping was conducted on the observed data. Conventionally, the results of the bootstrap are presented as a scatter plot on the cost effectiveness plan; however, to jointly present confidence interval around costs and outcomes a confidence ellipse is generated. This jointly indicates the incremental costs and QALYs on the 50%, 75% and 95% confidence intervals, indicating in the CE plane the probability space within which we are confident the true ICER is found.

To evaluate cost-effectiveness of our estimates against willingness-to-pay threshold of a health system decision maker, a range of maximum monetary values were used. To present how the probability of interventions being cost effect increases as decision makers willingness-to-pay increases, a cost effectiveness acceptability curve (CEAC) is generated.

Ethical approval
Our study protocol has been approved by the Primary Care Research Committee and the Mallorca Ethical Committee of Clinical Research (IB 1146/09 PI).

Results
At 12 months, data were available from 523/532 (98.3%) patients. The two structured educational interview programs were found to be more effective than usual care in stopping long-term benzodiazepine use over a 12-month period. The relative risks for benzodiazepine discontinuation were 3.01 (95% CI: 2.03 to 4.46) in the SIW and 3.00 (95% CI: 2.04 to 4.40) in the SIF group compared to usual care.

Unit cost, resource use and cost estimation.
Table 1 presents unit costs associated with benzodiazepine use and, as healthcare costs vary in Spanish regions, region-specific costs utilised to provide the GP cessation program are given within the three study regions.

To estimate the costs and cost consequences of implementing the cessation program, mean estimates of the use of healthcare resources associated with benzodiazepine use and cessation are calculated (see Table 2). This indicates the average number of GPs that attended training workshops per region and study group, the number of initial visits GPs provide to long-term users of benzodiazepines, and mean reported contact following initial visit. To indicate the consequence to the health care system, Table 2 indicates the proportion of study sample consuming specific benzodiazepine at initial visit, then at 6 and 12-month follow-up.

Applying unit cost to resource use, Table 3 estimates mean costs associated with the healthcare resources that are required.
Table 1. Unit costs associated with benzodiazepine use and cessation.

|                                | Quantity | Cost (€) | Unit  | Reference |
|--------------------------------|----------|----------|-------|-----------|
| **Initial GP visit (by region)** |          |          |       |           |
| Balearic Islands               | 1        | 62       | Per visit | BIOB 2012 |
| Catalunya                      | 1        | 40       | Per visit | DOGC 2012 |
| Valencia                       | 1        | 56.39    | Per visit | DOGV 2005 |
| **Follow-up visit (by region)** |          |          |       |           |
| Balearic Islands               | 1        | 32       | Per visit | BIOB 2012 |
| Catalunya                      | 1        | 40       | Per visit | DOGC 2012 |
| Valencia                       | 1        | 28.76    | Per visit | DOGV 2005 |
| **Prescribed benzodiazepines**  |          |          |       |           |
| Alprazolam 0.5                 |          | 0.50 mg  | 2.1   | MSSSI 2014 |
| Diazepam 5                     |          | 5 mg     | 1.9   | MSSSI 2014 |
| Lorazepamem                    |          | 1 mg     | 2     | MSSSI 2014 |
| Lorazepam                      |          | 1 mg     | 1.7   | MSSSI 2014 |
| Zolpidem                       |          | 10 mg    | 2.8   | MSSSI 2014 |
| Other benzodiazepine           |          | -        | 1.81  | MSSSI 2014 |

*Costs presented here of the commonly prescribed benzodiazepines are the weighted average. However, in the individual-level cost-analysis the specific costs per dose formulation is used.

Table 2. Mean use of healthcare resources associated with benzodiazepine use and cessation.

| Categories of resource use                          | SIW mean | SIW N | SIF mean | SIF N | TAU mean | TAU N |
|-----------------------------------------------------|-----------|-------|----------|-------|----------|-------|
| **GP attendance per workshop (N)**                  | 3         | 3     | 3        | 3     | 3        | 3     |
| Balearic Islands                                   | 4.5       | 2     | 4        | 2     | 5.5      | 2     |
| Catalunya                                           | 2         | 3     | 3        | 3     | 1.7      | 3     |
| Valencia                                            | 1         | 61    | 1        | 64    | 0        | 62    |
| **Initial visit to the GP for Benzodiazepines Cessation Program** | 1         | 60    | 1        | 56    | 0        | 76    |
| Balearic Islands                                   | 3.298     | 57    | 6.651    | 63    | 3.576    | 59    |
| Catalunya                                           | 2.424     | 59    | 4.727    | 55    | 2.135    | 74    |
| Valencia                                            | 4.022     | 45    | 8.103    | 68    | 2.471    | 34    |
| **Contact visits to the GP**                       | 1         | 47    | 1        | 71    | 0        | 35    |
| Balearic Islands                                   | 3.298     | 57    | 6.651    | 63    | 3.576    | 59    |
| Catalunya                                           | 2.424     | 59    | 4.727    | 55    | 2.135    | 74    |
| Valencia                                            | 4.022     | 45    | 8.103    | 68    | 2.471    | 34    |
| **Proportion of sample consuming specific benzodiazepine (over time):** |          |       |          |       |          |       |
| **Baseline**                                       | 0.179     | 168   | 0.199    | 191   | 0.150    | 173   |
| Alprazolam                                         | 0.089     | 168   | 0.115    | 191   | 0.052    | 173   |
| Diazepam                                           | 0.304     | 168   | 0.346    | 191   | 0.312    | 173   |
| Lorazepam                                          | 0.149     | 168   | 0.099    | 191   | 0.214    | 173   |
| Lormetazepam                                        | 0.149     | 168   | 0.099    | 191   | 0.214    | 173   |
### Table 3. Mean costs of healthcare resources associated with benzodiazepine use and cessation.

| Categories of resource use | SIW | SIF | TAU |
|----------------------------|-----|-----|-----|
|                            | Cost | N   | Cost | N   | Cost | N   |
| **Cost per GP workshop (€)** |      |     |      |     |      |     |
| Balearic Islands           | 468  | 3   | 543  | 3   | 0.00 | 3   |
| Catalunya                  | 466  | 2   | 541  | 2   | 0.00 | 2   |
| Valencia                   | 462  | 3   | 543  | 3   | 0.00 | 3   |
| **Cost of initial visit to the GP by participant** |      |     |      |     |      |     |
| Balearic Islands           | 62.00| 61  | 62.00| 64  | 0.00 | 62  |
| Catalunya                  | 40.00| 60  | 40.00| 56  | 0.00 | 76  |
| Valencia                   | 56.39| 47  | 56.39| 71  | 0.00 | 35  |
| **Cost of follow up visits to the GP by participant** |      |     |      |     |      |     |
| Balearic Islands           | 105.54| 57  | 212.83| 63 | 114.44| 59  |
| Catalunya                  | 96.95 | 59  | 189.09| 55 | 85.41 | 74  |
| Valencia                   | 160.89| 45  | 324.12| 68 | 98.82 | 34  |

*See Extended data32, 33*

**Mean initial visit to GP are informed by the ‘per-protocol’ approach in that each treatment group specified the incremental GP visit required to provide specific benzodiazepine cessation program.

***Given the wide array of benzodiazepines available, this resource use table only reports specific formulations with market share above 5%.
to provide the cessation program and the change in the cost of benzodiazepine in each group (no further extrapolation of cost-consequences beyond cost of benzodiazepine was done). Based on the available information, the mean total cost per patient over a 12 month period was €201.05 for SIW, €301.51 for SIF and €83.11 for TAU.

Health-state utility estimation

Individual HADS scores were used to estimate health-state utility values at each time point. Table 4 presents the unadjusted utilities by treatment group and time point. Applying area-under-the-curve approach and specifying accurate individual time intervals, unadjusted annual QALYs are estimated (see Table 5).

To control for individual-level variation in baseline utility and to estimate incremental QALYs for the intervention groups, ordinary least squares regression was used with baseline utility included as a covariate (Table 6 presents the regression outputs). The findings suggest that overall the model explains 56.06% of the variance in QALYs, that baseline utility is a significant predictor of change in QALYs, and the incremental QALY for SIW is 0.0144 (p=0.314) and for SIF is 0.0340 (p=0.014).

Incremental cost effectiveness analysis

The regression outputs suggest that baseline utility is a significant predictor overall QALY, so the adjusted coefficients are utilised to calculate point estimate of ICER. This indicates that the ICER for SIW is €8190.28/QALY and for SIF is €6423.53/QALY. However, examining 95% confidence intervals and statistical significance of the regression coefficients for SIW and SIF indicates a degree of uncertainty of the estimated health gain. To further explore the uncertainty surrounding the point estimate, confidence ellipses are generated based on non-parametric bootstrap (see Figure 1).

Examining these confidence ellipses, the shapes suggest that there exists significant variation in the incremental QALY than incremental cost. We can also conclude that at a 95% confidence

| Categories of resource use | SIW Cost | SIW N | SIF Cost | SIF N | TAU Cost | TAU N |
|----------------------------|---------|-------|----------|-------|----------|-------|
| Cost of benzodiazepine consumed (over time):                   |         |       |          |       |          |       |
| Baseline               |         |       |          |       |          |       |
| Alprazolam             | 4.50    | 168   | 5.01     | 191   | 3.79     | 173   |
| Diazepam               | 2.04    | 168   | 2.63     | 191   | 1.19     | 173   |
| Lorazepam              | 7.29    | 168   | 8.29     | 191   | 7.49     | 173   |
| Lorazepam              | 3.04    | 168   | 2.03     | 191   | 4.36     | 173   |
| Zolpidem               | 4.00    | 168   | 4.93     | 191   | 5.05     | 173   |
| Other Benzodiazepine   | 5.42    | 168   | 3.63     | 191   | 4.51     | 173   |
| 6 months               |         |       |          |       |          |       |
| Alprazolam             | 2.41    | 157   | 2.85     | 186   | 3.54     | 171   |
| Diazepam               | 2.18    | 157   | 4.05     | 186   | 1.60     | 171   |
| Lorazepam              | 3.21    | 157   | 2.58     | 186   | 3.23     | 171   |
| Lorazepam              | 1.30    | 157   | 1.65     | 186   | 4.41     | 171   |
| Zolpidem               | 2.57    | 157   | 2.17     | 186   | 3.93     | 171   |
| Other Benzodiazepine   | 2.90    | 157   | 2.56     | 186   | 5.71     | 171   |
| 12 months              |         |       |          |       |          |       |
| Alprazolam             | 2.55    | 168   | 2.64     | 191   | 3.64     | 173   |
| Diazepam               | 1.76    | 168   | 2.86     | 191   | 1.98     | 173   |
| Lorazepam              | 3.57    | 168   | 4.52     | 191   | 5.83     | 173   |
| Lorazepam              | 1.58    | 168   | 1.50     | 191   | 4.01     | 173   |
| Zolpidem               | 2.60    | 168   | 1.41     | 191   | 3.30     | 173   |
| Other Benzodiazepine   | 2.58    | 168   | 2.72     | 191   | 6.02     | 173   |
| Total Cost per Average Patient | 201.05 | 149   | 301.51   | 173   | 83.11    | 152   |

Total cost only reports specific formulations (over 5% market share) however in analysis specific unit cost applied (Full list of unit cost available on request from the author (see annex)).

*Average Exchange Rate: GBP/EURO (2012-13): 0.8141; GBP/USD (2012-13): 0.6325 [Sources: http://www.hmrc.gov.uk/exrate/exchangerates-1213.pdf].
level we are certain that the two programs will cost more but are less certain about incremental QALYs, particularly for the SIW group.

CEAC is generated to show how the probability that interventions will be cost effective as the decision-makers willingness-to-pay is increased (see Figure 2). The ICERs beyond which the interventions become more likely to be cost effectiveness are €8190.28/QALY (SIW) and €6423.53/QALY (SIF). This also illustrates that SIF has a higher certainty of being cost-effective.

At the commonly cited Spanish healthcare decision threshold of €45,000/QALY, the probability that SIW and SIF program being cost-effective was estimated to be P(ICER_{SIW}<45,000/QALY)=0.7983 and P(ICER_{SIF}<45,000/QALY)=0.9777, respectively.

**Discussion**

This study extends beyond a definitive intervention trial with a clinically significant finding and presents within-trial cost-effectiveness analysis of two strategies for benzodiazepine cessation. The incremental cost effectiveness ratios suggest that both forms of interventions may represent value for money as they fall below explicitly cited decision-makers willingness-to-pay threshold. This study presents findings that suggest that benzodiazepine cessation may be likely to improve individuals overall generic health state.

---

### Table 4. Unadjusted utilities by treatment group and time.

| Treatment group | Mean (s.d.) | Median | Min | Max | N  |
|-----------------|-------------|--------|-----|-----|----|
| SIW             |             |        |     |     |    |
| Baseline utility| 0.749 (0.165) | 0.775  | 0.257 | 1.000 | 160 |
| 6 months utility| 0.795 (0.152) | 0.826  | 0.346 | 1.000 | 159 |
| 12 months utility| 0.817 (0.174) | 0.875  | 0.224 | 1.000 | 155 |
| SIF             |             |        |     |     |    |
| Baseline utility| 0.731 (0.154) | 0.744  | 0.273 | 1.000 | 184 |
| 6 months utility| 0.799 (0.156) | 0.834  | 0.289 | 1.000 | 186 |
| 12 months utility| 0.811 (0.166) | 0.850  | 0.173 | 1.000 | 178 |
| TAU             |             |        |     |     |    |
| Baseline utility| 0.758 (0.158) | 0.773  | 0.338 | 1.000 | 168 |
| 6 months utility| 0.784 (0.152) | 0.816  | 0.346 | 1.000 | 171 |
| 12 months utility| 0.804 (0.163) | 0.834  | 0.349 | 1.000 | 160 |

### Table 5. Unadjusted annual QALYs.

| Treatment group | Mean (s.d.) | Median | Min | Max | N  |
|-----------------|-------------|--------|-----|-----|----|
| SIW             |             |        |     |     |    |
| 0.8681 (0.2014) | 0.8819      | -0.1066 | 1.6142 | 145 |
| SIF             |             |        |     |     |    |
| 0.8693 (0.1804) | 0.8870      | 0.3222  | 1.3249 | 169 |
| TAU             |             |        |     |     |    |
| 0.8622 (0.1756) | 0.8707      | 0.3694  | 1.1945 | 149 |

### Table 6. Regression analysis QALY controlling for baseline utility, treatment group.

| QALY              | Coefficient | Std. Err. | P>|t| | 95% Confidence Interval |
|-------------------|-------------|-----------|-----|------------------------|
| Baseline utility  | .8658       | .0356     | 24.30 | .000 | .796 | .9357 |
| SIW               | .0144       | .0143     | 1.01 | .314 | -.0137 | .0425 |
| SIF               | .0340       | .0138     | 2.46 | .014 | .0069 | .0612 |
| Constant          | .2020       | .0290     | 6.97 | .000 | .1453 | .2588 |

n= 463 R² = 0.5606
GP training on managing long-term benzodiazepine cessation is associated with health benefit to patients. Many benzodiazepines are available in Spain and there is no simple way to examine whether the level of potential health gain may be directly associated with withdrawal from products however comparison to usual care find a small but significant incremental cost that appears justified by the expected benefit in each intervention group. The perspective adopted was that of the healthcare payer (the Spanish Ministry of Health) and the calculation of total cost is based on intervention training costs, GP time and costs of benzodiazepine prescribed. The base-case does not extrapolate a model to indicate the adverse event or risk associated with long-term benzodiazepine use (e.g. falls, fractures, cognitive impairment or premature death). Such extrapolation could augment health-related quality of life (or costs to healthcare)
and hypothetically alter ICERs. However, as the cost of intervention justifies health gain, the approach adopted is already justified and, in the absence of a comprehensive measure of resource use, model-based augmentation would require assumptions and may simply raise more questions than answers.

Conversion of HADS score onto associated EQ5D utility was used to provide a means to estimate incremental QALYs. This approach has some limitation. Firstly, Brazier et al indicate that the relationship between the EQ-5D and HADS differed across the severity scale, where the concordance between the measures was higher at the less severe end of the scale. Secondly, health state utilities are based on the UK tariff. Finally, the use of HADS scores bases the estimate of generic health solely on changes in anxiety and depression and overlooks other potential domains of generic health (e.g. EQ5D illicit QALYs based on mobility, self-care, usual activities, pain/discomfort and anxiety/depression). In the absence of a preference-weighted measure of generic health (such as EQ5D), this provides an imperfect solution to estimate QALYs.

Nevertheless, analyses based on the currently available information are supportive of a wider implementation of GP training for benzodiazepine cessation in Spain. There does remain a level of uncertainty in the estimated results, as well as limitations in the costs and outcomes utilised and a healthcare decision-maker may alternatively commission further research. The confidence ellipse provides support that there is value in additional information, as it would suggest that the true ICER is most likely to lie in the top right quadrant of the cost effectiveness plane suggesting any further investment (either towards implementation or additional research) will likely represent value for money to the Spanish Ministry of Health.

**Data availability**

**Underlying data**

Zenodo: Cost-effectiveness of brief structured interventions to discontinue long-term benzodiazepine use: an economic analysis alongside a randomised controlled trial, [http://doi.org/10.5281/zenodo.3823846](http://doi.org/10.5281/zenodo.3823846)**.

**Extended data**

Zenodo: Supplemental 1: Full list of all benzodiazepine unit costs. Cost-effectiveness of brief structured interventions to discontinue long-term benzodiazepine use: an economic analysis alongside a randomised controlled trial, [https://doi.org/10.5281/zenodo.3835494](https://doi.org/10.5281/zenodo.3835494).

Zenodo: Supplemental 2: Costs associated with providing training workshops. Cost-effectiveness of brief structured interventions to discontinue long-term benzodiazepine use: an economic analysis alongside a randomised controlled trial [https://doi.org/10.5281/zenodo.3835506](https://doi.org/10.5281/zenodo.3835506).

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

---

**References**

1. Authier N, Balassassac D, Sautereau M, et al. Benzodiazepine dependence: focus on withdrawal syndrome. Am Pharm Fr. 2009; 67(6): 408–413. Elsevier Masson. [PubMed Abstract] [Publisher Full Text]

2. Ohayon MM, Lader MH: Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry. 2002; 63(9): 817–825. [PubMed Abstract] [Publisher Full Text]

3. Agencefrançaise de sécurité sanitaire des produits de santé (aissaps): État des lieux de la consommation des benzodiazépines en France. [monografía en internet]. Saint Denis (Paris) [consultado el 15 mar 2014]. 2012. [Reference Source]

4. BNF 65: British National Formulary, 65th edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain. 2013. [Reference Source]

5. National Institute for Health and Clinical Excellence (NICE): Guidance on the use of zopiclone, zolpidem and zopiclone for the short-term management of insomnia. [internet] London: National Institute for Health and Clinical Excellence (NICE), Technology Appraisal Guidance 77; 2004; [consultado el 14 abril 2014]. [Reference Source]

6. Grupo de Trabajo de la Guía de Práctica Clínica para el Manejo de Pacientes conTrastornos de Ansiedad en AtenciónPrimaria. Madrid: Plan Nacional para el SNS del MSC. Unidad de Evaluación de TecnologíasSanitarias. AgenciaLainEntralgo. Comunidad de Madrid; 2008. Guías de PrácticaClinica en el SNS -UETS Nº 2006/10. [Reference Source]

7. Grupo de Trabajo de la Guía de PrácticaClinica para el Manejo de Pacientes coninsomnio en AtenciónPrimaria. Guía de PrácticaClinica para el Manejo de Pacientes coninsomnio en AtenciónPrimaria. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad y Política Social. Unidad de Evaluación de TecnologíasSanitarias. AgenciaLainEntralgo. Comunidad de Madrid; 2009. Guías de PrácticaClinica en el SNS -UETS Nº 2007/5. [Reference Source]

8. Bejarano F, Pinol JL, Mora N, et al.: Elevado consumo de benzodiacepinas en mujeres ancianas asignadas a centros de salud urbanos de atención primaria/Incremento de benzodiacepinas en mujeres con 65 años o más en la atención primaria. Aten Primaria; 2008; 40(12): 617-621. [Publisher Full Text]

9. Agencia Española de Medicamentos y Productos Sanitarios. ObservatorioUso de Medicamentos: Utilización de medicamentosasociados a procedimientos con hipnoticos en España durante el periodo 2000-2012. Madrid: AEPSIS. 2014; [cited 15th mar 2014]. [Reference Source]

10. Khong TP, de Vries F, Goldberg JS, et al.: Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States. Calcif Tissue Int. 2012; 91(1): 24-31. [PubMed Abstract] [Publisher Full Text] [Free Full Text]

11. Glass J, Lantcot KL, Hermann N, et al.: Sedative hypnosis in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005; 331(7526): 1169. [PubMed Abstract] [Publisher Full Text] [Free Full Text]

12. Parr JM, Kavanagh DJ, Cahill L, et al.: Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta-analysis. Addiction. 2009; 104(1): 13–24. [PubMed Abstract] [Publisher Full Text]

13. Voshaar RC, Couvee JE, van Balkom AJ, et al.: Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry. 2006; 189: 213–220. [PubMed Abstract] [Publisher Full Text]
14. Vosahar RC, Krabbé P, Gorgels WJ, et al.: Tapering off Benzodiazepines in Long-term users: An Economic Evaluation. Pharmacoeconomics. 2006; 24(7): 683-694. PubMed Abstract | Publisher Full Text

15. Godfrey C, Heather N, Bowie A, et al.: Randomised controlled trial of two brief interventions against long-term benzodiazepine use: Cost-effectiveness. Addict Res Theory. 2008; 16(4): 309-317. Publisher Full Text

16. Vicens C, Bejarano F, Sempere E, et al.: Leiva. Comparative efficacy of two interventions to discontinue long-term benzodiazepine use: cluster randomised controlled trial in primary care. Br J Psychiatry. 2014; 204: 471-479. PubMed Abstract | Publisher Full Text

17. Drummond MF, O'Brien B, Stoddart GL, et al.: Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1997. Reference Source

18. Higgins JPT, Green S: Chapter 15: Incorporating economics evidence. Cochrane Handbook editor for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration. 2008. Reference Source

19. Brazier J: Measuring and valuing health benefits for economic evaluation. New York: Oxford University Press, 2007. Reference Source

20. National Institute for Clinical Excellence: Guide to the methods of technology appraisal. London: National Institute for Clinical Excellence. 2008. Reference Source

21. Rodriguez JM, Paz S, Lizan L, et al.: The use of quality-adjusted life-years in the economic evaluation of health technologies in Spain: a review of the 1990-2009 literature. Value Health. 2011; 14(4): 458-64. PubMed Abstract | Publisher Full Text

22. Resolución del director general del Servicio de Salud de modificación de los anexos 1 y 2 de la Orden de la consejera de Salud y Consumo de 22 de diciembre de 2006. DiariOficial de les IllesBalears, nº 40, (17 de marzo de 2012).

23. Orden SLT/42/2012, de 24 de febrero, para la aprovengenlesissupósiticoconceptorsfacturables is’aprovenelspublicscorespondentsalservesispreestalInstitut Catalá de la Salut. DiariOficial de la Generalitat de Catalunya Nº 6079,(2 de marzo de 2012).

24. Decretillegistatique de la Llei de Taxes de la Generalitat: Decretillegistatique 1/2005 de 25 de febrero, DiariOficial de la GeneralitatValenciana, nº, 2005; 4971. Reference Source

25. Agencia Española de Medicamentos y Productos Sanitarios. Farmacia: Información sobre los productos incluidos en la prestación farmacéutica del SNS (dispensables a través de oficinas de farmacia). Madrid: AEPS; [cited 15th mar 2014]; 2014. Reference Source

26. Dakin H: Review of studies mapping from quality of life or clinical measures to EQ-SD: an online database. Health and Quality of Life Outcomes. HERC database of mapping studies, Version 3.0 (Last updated: 26th June 2014). 2013; 11: 151. PubMed Abstract | Publisher Full Text | Free Full Text

27. Brazier J, Connell J, Papaioannou D, et al.: A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. Health Technol Assess. 2014; 18(34): vii-viii, xiii-xxv, 1–188. PubMed Abstract | Publisher Full Text | Free Full Text

28. Tyrer P, Thompson S, Schmidt U, et al.: Randomised controlled trial of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: the PDEPACT study. Psychol Med. 2003; 33(6): 969-76. PubMed Abstract | Publisher Full Text

29. Stinnett AA, Mullahy J: Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998; 18(2 Suppl): S68-S80. PubMed Abstract | Publisher Full Text

30. O’Brien B, Briggs A: Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res. 2002; 11(6): 455–468. PubMed Abstract | Publisher Full Text

31. Ferwick E, Claxton K, Sculpher M: Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ. 2001; 10(8): 779–787. PubMed Abstract | Publisher Full Text

32. Trepel D: Supplemental 1: Full list of all benzodiazepine unit costs. Cost-effectiveness of brief structured interventions to discontinue long-term benzodiazepine use: an economic analysis alongside a randomised controlled trial (Version 1). Zenodo. 2020. http://www.doi.org/10.5281/zenodo.383549

33. Trepel D: Supplemental 2 Costs associated with providing training workshops. Cost-effectiveness of brief structured interventions to discontinue long-term benzodiazepine use: an economic analysis alongside a randomised controlled trial. Zenodo. 2020. http://www.doi.org/10.5281/zenodo.383550

34. Leiva Rus A: Cost-effectiveness of brief structured interventions to discontinue long-term benzodiazepine use: an economic analysis alongside a randomised controlled trial. Zenodo. 2020. http://www.doi.org/10.5281/zenodo.382384
Open Peer Review

Current Peer Review Status: ✔️ ✔️

Version 1

Reviewer Report 20 July 2020

https://doi.org/10.21956/hrbopenres.14145.r27494

© 2020 Marti J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Joachim Marti

Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland

In this paper, the authors conduct a within-trial economic evaluation of brief interventions to discontinue long-term benzodiazepines use in the primary care setting in Spain. Specifically, they performed an incremental cost-effectiveness analysis of structured interviews with or without follow-up vs. usual care and find that both interventions are cost-effective, with ICERs well under the Spanish reimbursement threshold in both cases.

This is a particularly important topic and evidence is scarce regarding cost-effectiveness in this area. Long-term benzodiazepines use is a public health problem in most developing countries and studies are needed to show value for money of discontinuation strategies. This study therefore makes a valuable contribution to the literature.

The paper is methodologically sound and follows best practice guidelines in economic evaluation. It is well structured, and the analytical steps and assumptions are transparent. I have however a few comments and suggestions for clarification/possible improvement.

The abstract needs improvement in terms of style and content. Key information is lacking, especially the details on participants (GPs are mentioned, but brief details on patients included are needed, i.e. age range, definition of long-term use, etc.). Also, check consistency regarding direct (??) costs of long-term benzodiazepines use (figures in the abstract and in the text are not consistent). More generally, the paper would require some editing (e.g. check consistency of tense).

One important aspect is the definition of costs of benzodiazepines use, which is limited to direct drug costs in the paper, and more generally the scope of costs included. I would recommend clarifying the following statement (especially the last part) in the “Resource use and associated unit costs” section: “However, we restrict our consideration of cost to consider whether the health gains within the trial period justify the cost of the cessation programs plus subsequent
benzodiazepine use”. Also it is not fully clear whether GP cost is simply the unit cost of a GP visit multiplied by number of visits, or if broader costs were taken into account (including patient time costs) – there is conflicting information about this in the text. In addition, was the cost of training limited to trainer time or also included opportunity cost for trainees? Finally, the authors explain that estimating the benefits of benzo discontinuation in terms of avoided costs related to adverse events is challenging. This is true but they can be quite confident that their ICERs are conservative and this could be more emphasised in the text.

In terms of outcomes, mapping is used from HADS to QALYs to derive utility scores. Given the limitations of this approach (that are clearly stated), it could be useful to show results in terms of cost per HADS score change (cost-effectiveness) in addition to cost per QALY (cost-utility), and perhaps other expression of value such as cost per successful discontinuation (needs more details on how this was measured in the trial)?

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Partly

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Health economics, economic evaluation, addiction, health services research, empirical policy evaluation, health care financing

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 20 July 2020

https://doi.org/10.21956/hrbopenres.14145.r27496

© 2020 Kinsella S. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The paper is the first study to evaluate the cost effectiveness of this drug in this setting. Protocols seem to have been followed accurately from the methods section. The CEA seems accurately deployed. Costings at programme level were done and every effort at comprehensiveness seems to have been taken. ICER calculations controlling for baseline utility seem accurate at 95% CI.

The finding that both interventions are in fact cost-effective at 45k/QALY deserves a little more discussion.

There are some typos in the manuscript, e.g. discussion, first para, last sentence should read “hospitals”. Typographical issues I leave to the journal.

I recommend indexing.

Is the work clearly and accurately presented and does it cite the current literature?  
Yes

Is the study design appropriate and is the work technically sound?  
Yes

Are sufficient details of methods and analysis provided to allow replication by others?  
Yes

If applicable, is the statistical analysis and its interpretation appropriate?  
Yes

Are all the source data underlying the results available to ensure full reproducibility?  
Yes

Are the conclusions drawn adequately supported by the results?  
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Economics.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.